---
figid: PMC7773645__fphar-11-591393-g001
figtitle: NLRP3 inflammasome pathway associated with potential blockade sites of various
  pharmacological inhibitors to treat fibrosis
organisms:
- Candida dubliniensis
- Malus domestica
- Panax ginseng
- Salvia miltiorrhiza
- Artemisia annua
- Panax notoginseng
- Tripterygium wilfordii
- Polygonum cuspidatum
- Glycyrrhiza glabra
- Andrographis paniculata
- Pelargonium x hortorum
- Narcissus pseudonarcissus
- Pseudotsuga menziesii
- Isodon rubescens
- Abelmoschus manihot
- Bupleurum falcatum
- Oreocome striata
- Manulea altissima
- Larix sibirica
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Bos taurus
- Mycoplasmoides pneumoniae
pmcid: PMC7773645
filename: fphar-11-591393-g001.jpg
figlink: pmc/articles/PMC7773645/figure/F1/
number: F1
caption: The NLRP3 inflammasome pathway associated with potential blockade sites of
  various pharmacological inhibitors to treat fibrosis. NLRP3 (NOD-, LRR- and pyrin
  domain-containing 3) inflammasome in liver fibsosis could be inhibited by NLRP3
  inflammasome assembly inhibitors andrographolide (4) and oridonin (3, targeting
  the NACHT domain in NLRP3), mitochondrial DNA (mt DNA) de novo synthesis inhibitor
  sweroside (1), P2X purinoceptor 7 (P2X7) inhibitor 25-OCH3-PPD (6), Nrf2 pathway
  promotor quercetin (12) and pelargonidin (18), and platelet-derived growth factor-β
  receptor (PDGF-βR) inhibitor tetramethylpyrazine (25); NLRP3 inflammasome in renal
  fibsosis could be inhibited by nuclear factor (NF)-κB pathway inhibitors artemisinin
  (2), compound K (7), and icariin (17), Nrf2 pathway promotor astaxanthin (27), nicotinamide
  adenine dinucleotide phosphate oxidase 4 (NOX4) inhibitor ginsenoside Rg1 (8), ROS
  production inhibitor dihydroquercetin (13), autophagy activator pterostilbene (20),
  and X-linked inhibitor of apoptosis protein (XIAP) suppressant (22); NLRP3 inflammasome
  in cardiac fibsosis could be inhibited by NLRP3 inflammasome assembly inhibitor
  triptolide (5), CD36 inhibitor cinnamaldehyde (26), and TXNIP suppressant of crude
  extract salvianolates (Sal); NLRP3 inflammasome in pulmonary fibsosis could be inhibited
  by NLRP3 inflammasome assembly inhibitor lycorine (23, targeting the PYD of ASC),
  autophagy activator resveratrol (19), and NF-κB pathway inhibitor polydatin (21);
  NLRP3 inflammasome in synovial tissue fibsosis could be inhibited by hypoxia-inducible
  factors (HIF)-1α pathway inhibitor casticin (14); NLRP3 inflammasome in pancreatic
  fibrosis might be inhibited by autophagy activator saikosaponin A (10).
papertitle: Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis.
reftext: Nan Ding, et al. Front Pharmacol. 2020;11:591393.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9469142
figid_alias: PMC7773645__F1
figtype: Figure
organisms_ner:
- Bos taurus
- Mus musculus
- Homo sapiens
- Rattus norvegicus
redirect_from: /figures/PMC7773645__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7773645__fphar-11-591393-g001.html
  '@type': Dataset
  description: The NLRP3 inflammasome pathway associated with potential blockade sites
    of various pharmacological inhibitors to treat fibrosis. NLRP3 (NOD-, LRR- and
    pyrin domain-containing 3) inflammasome in liver fibsosis could be inhibited by
    NLRP3 inflammasome assembly inhibitors andrographolide (4) and oridonin (3, targeting
    the NACHT domain in NLRP3), mitochondrial DNA (mt DNA) de novo synthesis inhibitor
    sweroside (1), P2X purinoceptor 7 (P2X7) inhibitor 25-OCH3-PPD (6), Nrf2 pathway
    promotor quercetin (12) and pelargonidin (18), and platelet-derived growth factor-β
    receptor (PDGF-βR) inhibitor tetramethylpyrazine (25); NLRP3 inflammasome in renal
    fibsosis could be inhibited by nuclear factor (NF)-κB pathway inhibitors artemisinin
    (2), compound K (7), and icariin (17), Nrf2 pathway promotor astaxanthin (27),
    nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) inhibitor ginsenoside
    Rg1 (8), ROS production inhibitor dihydroquercetin (13), autophagy activator pterostilbene
    (20), and X-linked inhibitor of apoptosis protein (XIAP) suppressant (22); NLRP3
    inflammasome in cardiac fibsosis could be inhibited by NLRP3 inflammasome assembly
    inhibitor triptolide (5), CD36 inhibitor cinnamaldehyde (26), and TXNIP suppressant
    of crude extract salvianolates (Sal); NLRP3 inflammasome in pulmonary fibsosis
    could be inhibited by NLRP3 inflammasome assembly inhibitor lycorine (23, targeting
    the PYD of ASC), autophagy activator resveratrol (19), and NF-κB pathway inhibitor
    polydatin (21); NLRP3 inflammasome in synovial tissue fibsosis could be inhibited
    by hypoxia-inducible factors (HIF)-1α pathway inhibitor casticin (14); NLRP3 inflammasome
    in pancreatic fibrosis might be inhibited by autophagy activator saikosaponin
    A (10).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IRS1
  - NOX4
  - XIAP
  - AKT1
  - NLRP3
  - MNT
  - TXNIP
  - PYCARD
  - STS
  - MTOR
  - IL16
  - IL18
  - CD36
  - TLR4
  - TLR6
  - Irs1
  - Nox4
  - sal
  - Sall3
  - Stag1
  - Xiap
  - Akt1
  - Nlrp3
  - Mnt
  - Minute
  - Txnip
  - Pycard
  - Mtor
  - Nfkb1
  - Il16
  - Il18
  - Zdhhc21
  - Cd36
  - Scarb1
  - Tlr4
  - Tlr6
  - STAG1
  - AKT2
  - AKT3
  - NFKB1
  - S100A8
  - S100A9
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - Zfp335
  - NACHT
  - XIAP
---
